Alagebrium: Interim Phase IIa data

Interim data from an ongoing U.S. Phase IIa trial in 13 evaluable patients showed that alagebrium led to a 37.3% decrease in carotid augmentation, a measure of vascular stiffness, and a 41% decline in...